<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00696865</url>
  </required_header>
  <id_info>
    <org_study_id>D0970C00006</org_study_id>
    <nct_id>NCT00696865</nct_id>
  </id_info>
  <brief_title>AZD2624 Multiple Ascending Dose Study in Japan</brief_title>
  <acronym>JMAD</acronym>
  <official_title>A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2624 When Given in Multiple Ascending Oral Doses in Young Healthy Male Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This multiple ascending dose study will evaluate safety and tolerability after repeated
      ascending doses of AZD2624
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of multiple ascending oral doses of AZD2624 in young healthy male Japanese subjects compared to placebo by assessment of adverse events, vital signs, physical examinations, laboratory parameters, ECGs and EEGs</measure>
    <time_frame>All assessments are made at each visit, at least daily, during the study.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate and characterize the pharmacokinetics of AZD2624 and its metabolites when given orally in multiple ascending doses of AZD2624 to young healthy male Japanese subjects by assessment of drug concentration in plasma</measure>
    <time_frame>Blood samples will be taken before and after study drug administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of genes that influence the disposition, efficacy, safety and tolerability of AZD2624</measure>
    <time_frame>A single blood sample will be obtained</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <condition>Safety</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2624</intervention_name>
    <description>oral suspension, 3 doses</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy young male Japanese volunteers

        Exclusion Criteria:

          -  Significant illness, as judged by the investigator, within 2 weeks of screening visit
             or Day 1

          -  Enrollment in another concurrent investigational study or intake of an investigational
             drug within 4 months prior to the screening visit or Day 1

          -  Blood loss in excess of 200 mL within 30 days of screening visit or Day 1, in excess
             of 400 mL within 90 days of screening visit or Day 1, or in excess of 1200 mL within 1
             year of screening visit or Day 1

          -  Clinically relevant abnormalities in physical examinations, vital signs, clinical
             chemistry, hematology or urinalysis as judged by the investigator at screening or pre
             first dose
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuji Kumagai, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kitasato University East Hospital, Kanagawa, Japan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>June 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2008</study_first_posted>
  <last_update_submitted>July 15, 2009</last_update_submitted>
  <last_update_submitted_qc>July 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mark A. Smith, MD, PhD - Medical Science Sr. Director</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Phase I</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

